Quality of Life Office Workshops 

 

The current COVID-19 restrictions are posing significant challenges for research, particularly with many of us trying to balance working from home and physical distancing with increased clinical loads and family responsibilities. We appreciate this may limit your capacity to engage our services.

During this difficult time, we remain committed to ensuring that all cancer clinical trials group (CCTG) members and staff developing concepts, grant applications, and research projects with patient-reported outcomes (PROs) continue to receive full support from the Quality of Life Technical Service.

In response, we are replacing face-to-face workshops and presentations with online options. We’ll be uploading a series of online educational presentations that you can access over the coming weeks (the first is available now – please see details below).

Please also note that most of our resources are already online and accessible to all CCTG members and staff. The best way to contact us directly is via our online query form or by email.

 

Presentation Recordings

 

Short Education Presentations on PROs in clinical research.

A series of three educational presentations covering the basic considerations for collecting PROs in clinical trial research. Recommended for all new CCTG staff, and new investigators considering collecting PROs in their studies. (~ 15 minutes each)

 

1.  What is Quality of Life? Definitions and Terminology

 When prompted, enter the access code: QOL-TS

 

2. How to select a Patient-Reported Outcome Measure: Coming soon

 

3. Principles of good Patient-Reported Outcome research design: Coming soon

 

WEBINAR RECORDINGS

 

Interpreting Quality of Life and other Patient-Reported Outcomes

Quality of Life (QOL) and other patient-reported outcomes (PROs) provide information about the impact of disease and treatment on the patient.

QOL/PROs should be interpreted in the context of other trial outcomes to provide a comprehensive assessment of treatment benefits and harms. Statistical significance alone is not a sufficient means of interpreting changes in PRO scores in a way that is clinically meaningful.

 

In this Webinar you will learn:

  • How to interpret QOL PROs in a clinically meaningful way
  •  Current approaches to determining the smallest difference in a PRO that matters
 
 

 Presenter: Prof Madeleine King 

 Cancer Australia Chair in Cancer Quality of Life (QoL), Director of the QoL Office,  Psycho-oncology Co-operative Research Group (PoCoG), School of   Psychology, University of Sydney. NSW, Australia

 

 This workshop was held in April 2017